Potential Benefits
- Improved immune markers in clinical settings (e.g., hepatitis B studies)
- General immune support
Immune SupportInflammationCellular RepairImmune optimization and supportAdjunctive use in chronic viral or immune-compromised states
RESEARCH REFERENCE
Thymosin Alpha-1
Immune-modulating peptide used for immune support and as an adjuvant in certain conditions.
01
Quick Reference
- Dose
- 1.6 mg (clinical standard)
- Frequency / schedule
- 2× weekly (or 5-on/2-off in some protocols)
- Route
- Subcutaneous
- Timing
- Morning preferred
- Fasting
- Not required
- Cycle
- 8–16 weeks (or longer for chronic use)
- Time off
- Reassess after course
- Common vial strengths
- 5 mg, 10 mg
02
How this works
Thymosin Alpha-1 enhances T-cell function, promotes differentiation and maturation of T-lymphocytes, and modulates cytokine production, supporting both innate and adaptive immunity.
03
Benefits + side effects
Side Effects
- Generally well tolerated
- Mild injection-site reactions
02
Dosing / Protocol
Reference Protocol
| Phase / week | Dose | Frequency | Timing | Notes |
|---|---|---|---|---|
| Standard | 1.6 mg | 2× weekly (e.g. Mon/Thu) | Morning | Clinical reference dose |
| Alternative | 1.5–1.6 mg | 5 days on / 2 off | Morning | Community variation |
Timing + Fasting Notes
Morning preferred. Food does not matter.
03
Reconstitution
Approved preparation example
Calculate for 1.6 mg doses (note: dosed in mg, not mcg).
04
Practical Reference
- Storage
- Refrigerated reconstituted
- Route / injection context
- Subcutaneous
- Common vial strengths
- 5 mg, 10 mg
- Cycle / time off
- 8–16 weeks (or longer for chronic use) · Reassess after course
- Practical notes
- Standard clinical dose is 1.6 mg — do not confuse with mcg-range peptides. Research / clinical use.
10
References
Thymosin alpha 1 for severe sepsis: a multicentre, randomized, controlled clinical trialIntensive Care Medicine · 2013
CLINICAL TRIALTHE SIGNAL · SENT TWICE A MONTH